Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Randomized n-of-1 Trials: Quality Improvement, Research, or Both? Pediatrics Samuel, J. P., Burgart, A., Wootton, S. H., Magnus, D., Lantos, J. D., Tyson, J. E. 2016; 138 (2)

Abstract

The regulatory demarcations between clinical research and quality improvement (QI) are ambiguous and controversial. Some projects that were undertaken as a form of QI were deemed by regulatory agencies to be research and thus to require institutional review board approval. In the era of personalized medicine, some physicians may ask some patients to participate in n-of-1 trials in an effort to personalize and optimize each patient's medical treatment. Should such activities be considered research, QI, or just excellent personalized medicine? Experts in research, research regulation, and bioethics analyze these issues.

View details for DOI 10.1542/peds.2016-1103

View details for PubMedID 27385811